Randomized Controlled Pilot Trial of Pregnenolone in Autism

Who is this study for? Child to young adult patients with Autism Spectrum Disorder
What treatments are being studied? Pregnenolone
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY

This is a research study to examine the tolerability and effectiveness of pregnenolone in individuals with autism. Pregnenolone is a naturally occurring steroid hormone in the brain that has been implicated in treating various psychiatric conditions. The investigators hope to learn the effects and safety of using pregnenolone in reducing irritability and sensitivity to sensory differences and improving social communication in individuals with autism. The investigators hope by studying the effects of pregnenolone in more detail, the investigators can design better ways to treat individuals with autism.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 14
Maximum Age: 25
Healthy Volunteers: f
View:

• outpatients between 14 and 25 years of age with a Tanner stage of IV or V;

• male and female subjects who were physically healthy;

• diagnosis of Autism Spectrum Disorder (ASD) based on DSM-5, expert clinical opinion and confirmed with Autism Diagnostic Interview - Revised (ADI-R) and either Autism Diagnostic Observation Schedule (ADOS) or Childhood Autism Rating Scale (CARS-2);

• Aberrant Behavior Checklist -Irritability (ABC-I)≥ 18 and Clinical Global Impression (CGI)-Severity subscale ≥ 4;

• stable concomitant medications for at least 2 weeks;

• no planned changes in psychosocial interventions during the trial.

Locations
United States
California
Stanford University School of Medicine
RECRUITING
Stanford
Contact Information
Primary
Briana Hernandez
autismdd@stanford.edu
(650) 736-1235
Backup
Robin Libove
rlibove@stanford.edu
(650) 736-1235
Time Frame
Start Date: 2016-01-29
Estimated Completion Date: 2026-05
Participants
Target number of participants: 40
Treatments
Experimental: Pregnenolone (up to 500 mg per day)
Twice daily intake of orally administered Pregnenolone will occur on a schedule as described below.~Weeks 1 and 2: 30mg twice daily (total 60mg per day)~Weeks 3 and 4: 60mg twice daily (total: 120mg per day)~Weeks 5 and 6: 90mg twice daily (total: 180mg per day)~Weeks 7 and 8: 150mg twice daily (total: 300mg per day)~Weeks 9 and 10: 210mg twice daily (total: 420mg per day)~Weeks 11 to 14: 250mg twice daily (total: 500mg per day)
Placebo_comparator: Placebo
Placebo
Related Therapeutic Areas
Sponsors
Leads: Stanford University
Collaborators: Simons Foundation

This content was sourced from clinicaltrials.gov